肝硬化上消化道出血患者的预防性抗生素:系统评价与贝叶斯Meta分析
该系统评价与贝叶斯Meta分析纳入14项RCT共1322例肝硬化上消化道出血患者(平均年龄41.5至62.0岁,981例男性[74.2%],1202例[90.9%]为静脉曲张性出血),比较较长疗程与较短疗程(或0天)预防性抗生素。较短疗程(含不用)在全因死亡率上不劣于较长疗程的概率为97.3%(RD 0.9%,95%CrI -2.6至4.9),早期再出血不劣于的概率为73.8%(RD 2.9%,95%CrI -4.2至10.0),但研究定义的细菌感染更多(RD 15.2%,95%CrI 5.0至25.9)。研究质量低至中等,感染定义异质,无研究报告不良事件。作者认为现有证据不支持指南推荐所依据的死亡率获益,需更高质量RCT确定现代最佳疗程。
要点
- 较短疗程(含0天)预防性抗生素全因死亡率不劣于较长疗程的概率97.3%(RD 0.9%,95%CrI -2.6至4.9)。
- 较短疗程早期再出血不劣于较长疗程的概率仅73.8%(RD 2.9%,95%CrI -4.2至10.0)。
- 较短疗程研究定义的细菌感染更多(RD 15.2%,95%CrI 5.0至25.9),但感染定义异质、偏倚风险高。
- 作者认为现有证据不支持指南推荐所依据的死亡率获益,当前指南推荐并非基于高质量证据。
- 2004年后发表的研究中,较短疗程对全部3项结局的不劣于概率更高。
适用人群与场景
- 纳入:肝硬化合并上消化道出血的成人患者,随机对照试验人群平均年龄范围41.5至62.0岁,981例男性(74.2%),1202例(90.9%)为静脉曲张性出血。
- 排除:观察性研究、儿科研究、灰色文献、全身抗生素之间比较的研究、未报告死亡率或早期再出血的研究、非全身抗生素的研究。
研究设计与关键结果
- 研究类型:系统评价与贝叶斯Meta分析,纳入14项RCT共1322例患者。
- 干预与对照:2项RCT比较较长疗程(5-7天)与较短疗程(2-3天),12项RCT比较任何预防性抗生素(1-10天)与不用。
- 主要终点:全因死亡率,预设非劣效界值为风险差(RD)5%;较短疗程(含不用)不劣于较长疗程的概率97.3%(RD 0.9%,95%CrI -2.6至4.9)。
- 关键次要终点:早期再出血不劣于概率73.8%(RD 2.9%,95%CrI -4.2至10.0);研究定义的细菌感染更多(RD 15.2%,95%CrI 5.0至25.9)。
- 亚组:2004年后发表的研究中,较短疗程对全部3项结局的不劣于概率更高。
- 不良事件:无研究报告不良事件。
证据类型、等级与局限
- 证据类型:系统评价与贝叶斯Meta分析,纳入14项随机对照试验。
- 证据质量:研究质量低至中等,细菌感染定义异质,无研究报告不良事件。
- 局限:研究质量低至中等;细菌感染定义异质;无研究报告不良事件;作者指出需更高质量RCT确定现代最佳疗程。
对床旁实践的改变
- 作者认为现有证据不支持指南推荐所依据的死亡率获益,临床医生应知晓当前指南推荐并非基于高质量证据。
- 作者指出需更高质量RCT确定现代先进干预时代预防性抗生素的获益与最佳疗程。
- 较短疗程(含不用)在研究定义的细菌感染上更多(RD 15.2%,95%CrI 5.0至25.9),但感染定义异质、偏倚风险高。
指南或共识出处
- 国际指南推荐肝硬化上消化道出血患者预防性使用抗生素5至7天(原文引用,未列具体指南名称)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: International guidelines recommend 5 to 7 days of antibiotic prophylaxis for patients with cirrhosis and upper gastrointestinal bleeding. However, the evidence for this recommendation has not been reassessed recently.
OBJECTIVE: To determine whether current evidence continues to support the recommended 5 to 7 days of antibiotic prophylaxis in patients with cirrhosis and upper gastrointestinal bleeding.
DATA SOURCES: Searches were performed of the Embase, MEDLINE, and CENTRAL databases for randomized clinical trials (RCTs) from inception to September 25, 2024. The search query included the keywords gastrointestinal bleeding and prophylactic antibiotics.
STUDY SELECTION: Included RCTs compared longer durations of antibiotic prophylaxis to shorter durations (or 0 days) in patients with cirrhosis and upper gastrointestinal bleeding. Observational and pediatric studies, gray literature, comparisons of systemic antibiotics, studies not reporting mortality or early rebleed, and studies of nonsystemic antibiotics were excluded.
DATA EXTRACTION AND SYNTHESIS: Data were extracted in duplicate by independent reviewers. Study quality was assessed in duplicate using the Cochrane Risk of Bias 2 tool. Data were pooled by random-effects bayesian meta-analyses using a noninformative prior for the effect and a weakly informative prior for heterogeneity. To account for therapeutic advancements, a post hoc subgroup analysis was performed for studies published after 2004.
MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality with a prespecified 5% noninferiority margin on the risk difference (RD) scale. Early rebleed and bacterial infections were secondary outcomes.
RESULTS: The analysis included 14 RCTs totaling 1322 participants (mean age range, 41.5 to 62.0 years; 981 male [74.2%] individuals), of whom 1202 (90.9%) had a variceal source of bleeding. Study quality was low to moderate, bacterial infections were heterogeneously defined, and no studies reported adverse events. Two RCTs compared longer (5-7 days) to shorter (2-3 days) durations and 12 RCTs compared any prophylaxis (1-10 days) to none. Shorter durations (including none) had a 97.3% probability of noninferiority for all-cause mortality (RD, 0.9%; 95% credible interval [95% CrI], -2.6 to 4.9). Shorter durations had a 73.8% probability of noninferiority for early rebleeding (RD, 2.9%; 95% CrI, -4.2 to 10.0) but were associated with more study-defined bacterial infections (RD, 15.2%; 95% CrI, 5.0 to 25.9). The probabilities of noninferiority of shorter durations for all 3 outcomes were higher in studies published after 2004.
CONCLUSIONS AND RELEVANCE: The findings of this systematic review and bayesian meta-analysis do not support the purported mortality benefit driving guideline recommendations for antibiotic prophylaxis in patients with cirrhosis and upper gastrointestinal bleeds. Although prophylaxis reduced reported infections, methodological concerns regarding infection definitions introduced high risk of bias. Higher-quality RCTs are needed to determine the benefit and optimal duration of antibiotic prophylaxis in the modern era of advanced interventions. Until these studies are available, clinicians should be aware that the current guideline recommendations are not based on high-quality evidence.
参考来源
- Prosty C, Noutsios D, Dubé LR, et al. Prophylactic Antibiotics for Upper Gastrointestinal Bleeding in Patients With Cirrhosis: A Systematic Review and Bayesian Meta-Analysis. JAMA Intern Med. 2025. PMID: 40788637. doi:10.1001/jamainternmed.2025.3832
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。